Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRTNASDAQ:GELSNASDAQ:MGXNASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.66+1.5%$0.64$0.51▼$1.80$63.39M0.32664,210 shs145,315 shsGELSGelteq$1.69-1.2%$1.52$0.77▼$5.50$15.95MN/A1.00 million shs10,169 shsMGXMetagenomi$1.73+4.2%$1.59$1.23▼$6.90$64.67M-0.33797,099 shs502,021 shsOTLKOutlook Therapeutics$1.90+1.6%$1.54$0.87▼$9.25$63.78M0.39787,720 shs663,369 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+1.50%-1.59%+7.24%-15.36%-33.80%GELSGelteq-1.17%+8.33%+18.68%+32.04%+168,999,900.00%MGXMetagenomi+4.22%+2.35%+19.72%-16.43%-73.59%OTLKOutlook Therapeutics+1.60%+2.70%+34.75%+27.52%-73.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio1.3782 of 5 stars3.50.00.00.00.60.81.3GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AMGXMetagenomi2.0172 of 5 stars3.53.00.00.02.60.80.0OTLKOutlook Therapeutics1.8332 of 5 stars3.43.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 3.00Buy$2.75315.53% UpsideGELSGelteq 0.00N/AN/AN/AMGXMetagenomi 3.00Buy$13.00651.45% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$9.60405.26% UpsideCurrent Analyst Ratings BreakdownLatest GELS, OTLK, ASRT, and MGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.005/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.005/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.005/13/2025ASRTAssertioAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025MGXMetagenomiHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $7.003/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.503/18/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.003/14/2025ASRTAssertioIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$1.75(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$119.00M0.53$0.59 per share1.12$1.46 per share0.45GELSGelteqN/AN/AN/AN/AN/AN/AMGXMetagenomi$45.26M1.43N/AN/AN/A∞OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$331.94M-$0.32N/A22.063.25-54.46%3.79%1.81%8/6/2025 (Estimated)GELSGelteqN/AN/A0.00∞N/AN/AN/AN/AN/AMGXMetagenomi-$68.25M-$2.11N/AN/AN/A-134.27%-43.23%-18.86%8/13/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)Latest GELS, OTLK, ASRT, and MGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/13/2025Q1 2025MGXMetagenomi-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million3/17/2025Q4 2024MGXMetagenomi-$0.62-$0.63-$0.01-$0.63$13.18 million$9.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.302.011.57GELSGelteqN/AN/AN/AMGXMetagenomiN/A6.186.18OTLKOutlook TherapeuticsN/A0.320.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%GELSGelteqN/AMGXMetagenomiN/AOTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%GELSGelteqN/AMGXMetagenomi17.80%OTLKOutlook Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2095.78 million92.42 millionOptionableGELSGelteqN/A9.44 millionN/AN/AMGXMetagenomi23637.38 millionN/AN/AOTLKOutlook Therapeutics2033.57 million30.48 millionOptionableGELS, OTLK, ASRT, and MGX HeadlinesRecent News About These CompaniesHighlights | Outlook Planet’s C³ Summit & Awards 2025June 7 at 1:46 AM | outlookbusiness.comNatural Gas Price Outlook – Natural Gas Continues to See Same Resistance LevelJune 7 at 1:46 AM | fxempire.comOilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 MomentJune 7 at 1:46 AM | msn.comChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New PricingJune 7 at 1:46 AM | techrepublic.comOutlook Therapeutics (NASDAQ:OTLK) Given New $21.00 Price Target at Ascendiant Capital MarketsJune 6 at 8:19 AM | marketbeat.comOutlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMDJune 4 at 12:24 AM | pharmabiz.comOutlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMDJune 2, 2025 | globenewswire.comQ3 EPS Estimate for Outlook Therapeutics Boosted by AnalystMay 31, 2025 | marketbeat.comAnalysts Issue Forecasts for OTLK FY2026 EarningsMay 31, 2025 | americanbankingnews.comQ3 EPS Forecast for Outlook Therapeutics Boosted by AnalystMay 31, 2025 | americanbankingnews.comBrookline Capital Management Forecasts OTLK FY2026 EarningsMay 30, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by AnalystsMay 24, 2025 | marketbeat.comOutlook Therapeutics announces public stock offeringMay 24, 2025 | investing.comOutlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and WarrantsMay 24, 2025 | nasdaq.comOutlook Therapeutics announces proposed public offering of common stock, warrantsMay 23, 2025 | msn.comOutlook Therapeutics drops 17%, prices $13M stock offeringMay 23, 2025 | msn.comOutlook Therapeutics® Announces Pricing of $13.0 Million Public OfferingMay 23, 2025 | globenewswire.comOutlook Therapeutics® Announces Proposed Public Offering of Common Stock and WarrantsMay 22, 2025 | globenewswire.comTang Capital Management LLC Has $345,000 Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)May 21, 2025 | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deOutlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGELS, OTLK, ASRT, and MGX Company DescriptionsAssertio NASDAQ:ASRT$0.66 +0.01 (+1.50%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.67 +0.01 (+1.09%) As of 06/6/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Gelteq NASDAQ:GELS$1.69 -0.02 (-1.17%) As of 06/6/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Metagenomi NASDAQ:MGX$1.73 +0.07 (+4.22%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.73 0.00 (0.00%) As of 06/6/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Outlook Therapeutics NASDAQ:OTLK$1.90 +0.03 (+1.60%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.89 -0.01 (-0.53%) As of 06/6/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
